Low-impact ampakine CX717 exhibits promising therapeutic profile in adults with ADHD – A phase 2A clinical trial

CX717, a low-impact ampakine, is a positive allosteric modulator of AMPA-glutamate receptors. This clinical study evaluated CX717 for the treatment of ADHD symptomology in a randomized, double-blind, placebo-controlled, multi-center, 2-period crossover with two doses of CX717 (200 or 800 mg BID). Each treatment period lasted 3 weeks with a 2-week washout. Subjects met DSM-IV criteria for adult ADHD and had moderate to severe symptoms. The primary efficacy measure was the change from baseline on…

via https://pubmed.ncbi.nlm.nih.gov/40783159/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1lqZ3NPYysePVKsoyz66mDSgu4veDGJwnUBS47TBQPoOuNZY5J&fc=None&ff=20250825011006&v=2.18.0.post9+e462414